NBC News @NBCNews
Viatris Inc, the drugmaker formerly known as Mylan, says it has agreed to pay $264,000,000 to resolve a class-action lawsuit alleging it engaged in a scheme to delay generic competition to its EpiPen allergy treatment. https://t.co/2f4IInhKGr — PolitiTweet.org